Search results
Showing 61 to 75 of 129 results for epilepsy
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...
temazepam. Benzodiazepines can also be used for other conditions, such as epilepsy. Talk to your healthcare professional if this applies...
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting...
Antisocial behaviour and conduct disorders in children and young people (QS59)
This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.
View quality statements for QS59Show all sections
Sections for QS59
- Quality statements
- Quality statement 1: Early intervention
- Quality statement 2: Comprehensive assessment
- Quality statement 3: Improving access to services
- Quality statement 4: Parent or carer training
- Quality statement 5: Multimodal interventions
- Quality statement 6: Monitoring adverse effects of pharmacological interventions
- Update information
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
project. Patients taking long term BDZ were determined (patients with epilepsy and end of life were excluded) and a letter stating the...
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS51Show all sections
Sections for QS51
- Quality statements
- Quality statement 1: Diagnostic assessment by an autism team
- Quality statement 2: Assessment and diagnosis
- Quality statement 3: Personalised plan
- Quality statement 4: Coordination of care and support
- Quality statement 5: Treating the core features of autism: psychosocial interventions
- Quality statement 6: Treating the core features of autism: medication
- Quality statement 7: Assessing possible triggers for behaviour that challenges
Transcranial magnetic stimulation for auditory hallucinations (IPG680)
Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.
View recommendations for IPG680Show all sections
TA059 Electroconvulsive Therapy (ECT) 12 February 2003 TA076 Epilepsy (adults) - newer drugs 19 January 2004 TBC Erenumab for treating
cognitive) and behavioural outcomes in children born to women and girls with epilepsy (these should be undertaken on a long-term basis...